Actinogen Medical Limited (AU:ACW)

Actinogen Medical Limited (ACW) Income Statement


Actinogen Medical Limited Income Statement

Last quarter (Q4 2022), Actinogen Medical Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Actinogen Medical Limited's net income was AU$―. See Actinogen Medical Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
----AU$ 80.82K-
Cost of Revenue
Gross Profit
----AU$ 80.82K-
Operating Expense
-AU$ 13.17MAU$ 5.90MAU$ 8.91MAU$ 14.47MAU$ 9.56M
Operating Income
-AU$ -13.17MAU$ -5.90MAU$ -8.91MAU$ -14.47MAU$ -9.56M
Net Non Operating Interest Income Expense
-AU$ 22.59KAU$ 4.77KAU$ 65.17KAU$ 196.56KAU$ 27.26K
Other Income Expense
-AU$ 3.65MAU$ 1.98MAU$ 3.52MAU$ 4.39MAU$ 3.30M
Pretax Income
-AU$ -9.50MAU$ -3.92MAU$ -5.33MAU$ -9.89MAU$ -6.23M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-AU$ -9.50MAU$ -3.92MAU$ -5.33MAU$ -9.89MAU$ -6.23M
Basic EPS
-AU$ >-0.01AU$ >-0.01AU$ >-0.01AU$ >-0.01-
Diluted EPS
-AU$ >-0.01AU$ >-0.01AU$ >-0.01AU$ >-0.01-
Basic Average Shares
-AU$ 1.72BAU$ 1.41BAU$ 1.14BAU$ 1.12B-
Diluted Average Shares
-AU$ 1.72BAU$ 1.41BAU$ 1.14BAU$ 1.12B-
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
Net Income From Continuing And Discontinued Operation
-AU$ -9.50MAU$ -3.92MAU$ -5.33MAU$ -9.89MAU$ -6.23M
Normalized Income
-AU$ -9.50MAU$ -3.92MAU$ -5.33MAU$ -9.41MAU$ -6.23M
Interest Expense
-AU$ 18.48KAU$ 22.32KAU$ 28.88KAU$ 7.99KAU$ 11.46K
-AU$ -9.48MAU$ -3.89MAU$ -5.30MAU$ -9.88MAU$ -6.22M
-AU$ -9.08MAU$ -3.51MAU$ -4.89MAU$ -9.53MAU$ -5.86M
Currency in AUD

Actinogen Medical Limited Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis